Home › Companies › XENON PHARMACEUTICALS INC. › 2024-2025
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and XENON PHARMACEUTICALS INC.’s Form 8-K, filed June 5, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 4, 2025: 11 items on XENON PHARMACEUTICALS INC.’s Form 8-K, filed June 5, 2025: 8 elected · 3 approved.
No notable dissent.
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore XENON PHARMACEUTICALS INC. in the interactive database Compare manager voting policies
These tallies are XENON PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 5, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Dawn Svoronos | 66,244,095 | 3,593,715 | -- | -- | 2,237,919 | 95% | Elected | — |
| Elect Director: Gillian Cannon | 68,942,319 | 895,491 | -- | -- | 2,237,919 | 99% | Elected | — |
| Elect Director: Steven Gannon | 69,048,114 | 789,696 | -- | -- | 2,237,919 | 99% | Elected | — |
| Elect Director: Elizabeth Garofalo | 68,942,869 | 894,941 | -- | -- | 2,237,919 | 99% | Elected | — |
| Elect Director: Justin Gover | 68,866,647 | 971,163 | -- | -- | 2,237,919 | 99% | Elected | — |
| Elect Director: Patrick Machado | 64,129,706 | 5,708,104 | -- | -- | 2,237,919 | 92% | Elected | — |
| Elect Director: Ian Mortimer | 69,082,169 | 755,641 | -- | -- | 2,237,919 | 99% | Elected | — |
| Elect Director: Gary Patou | 68,936,669 | 901,141 | -- | -- | 2,237,919 | 99% | Elected | — |
| 2. Advisory Vote on Compensation of Named Executive Officers ("Say-on-Pay") | 67,252,200 | 2,125,675 | 459,935 | -- | 2,237,919 | 97% | Approved | — |
| 3. Appointment of Auditor | 72,041,362 | -- | -- | 34,367 | 0 | 99.9% | Approved | — |
| 4. Remuneration of Auditor | 72,040,092 | 24,835 | 10,802 | -- | 0 | 99.9% | Approved | — |
Source: XENON PHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 5, 2025 — read the filing on EDGAR.
See voting trends for Health Care companies, 2024-2025: shareholder support by sector and by company size.
210 asset managers disclosed a vote on at least one XENON PHARMACEUTICALS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of XENON PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 4 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Prior year: 93.2% for (June 4, 2024 meeting) ▲ 1.7 pts
Description as filed by funds: To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Dawn Svoronos
XENON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Dawn Svoronos”): 66,244,095 for, 3,593,715 against, per its Form 8-K filed June 5, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The following nominees were elected as directors to serve until the 2026 annual meeting of shareholders or until their respective successors are duly elected and qualified:”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 63 asset managers below reported 25,699,826 for, 71,365 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 7,926,499 | 0 | 0 | 0 | For |
| Capital Group | 5,394,151 | 0 | 0 | 0 | For |
| Vanguard | 2,806,672 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,129,206 | 0 | 0 | 0 | For |
| JPMorgan | 765,468 | 0 | 0 | 0 | For |
| Prudential/PGIM | 686,997 | 0 | 0 | 0 | For |
| BlackRock | 661,541 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 658,823 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 499,260 | 0 | 0 | 0 | For |
| AllianceBernstein | 447,152 | 0 | 0 | 0 | For |
| Aberdeen | 437,109 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 399,759 | 0 | 0 | 0 | For |
| Loomis Sayles | 391,275 | 0 | 0 | 0 | For |
| T. Rowe Price | 317,655 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 316,679 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 277,719 | 0 | 0 | 0 | For |
| Federated Hermes | 232,500 | 0 | 0 | 0 | For |
| Putnam | 229,040 | 0 | 0 | 0 | For |
| BNY Mellon | 152,329 | 0 | 0 | 0 | For |
| Dimensional | 134,251 | 0 | 0 | 0 | For |
| Invesco | 133,507 | 0 | 0 | 0 | For |
| Equitable | 120,169 | 0 | 0 | 0 | For |
| Goldman Sachs | 115,350 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 103,619 | 0 | 0 | 0 | For |
| BARON SELECT FUNDS | 100,100 | 0 | 0 | 0 | For |
Showing the 25 largest of 63 asset managers. All 63 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Prior year: 94.5% for (June 4, 2024 meeting) ▲ 4.2 pts
Description as filed by funds: To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Elizabeth Garofalo
XENON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Elizabeth Garofalo”): 68,942,869 for, 894,941 against, per its Form 8-K filed June 5, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The following nominees were elected as directors to serve until the 2026 annual meeting of shareholders or until their respective successors are duly elected and qualified:”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 63 asset managers below reported 25,761,595 for, 9,596 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 7,926,499 | 0 | 0 | 0 | For |
| Capital Group | 5,394,151 | 0 | 0 | 0 | For |
| Vanguard | 2,806,672 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,129,206 | 0 | 0 | 0 | For |
| JPMorgan | 765,468 | 0 | 0 | 0 | For |
| Prudential/PGIM | 686,997 | 0 | 0 | 0 | For |
| BlackRock | 661,541 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 658,823 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 499,260 | 0 | 0 | 0 | For |
| AllianceBernstein | 447,152 | 0 | 0 | 0 | For |
| Aberdeen | 437,109 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 399,759 | 0 | 0 | 0 | For |
| Loomis Sayles | 391,275 | 0 | 0 | 0 | For |
| T. Rowe Price | 317,655 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 316,679 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 277,719 | 0 | 0 | 0 | For |
| Federated Hermes | 232,500 | 0 | 0 | 0 | For |
| Putnam | 229,040 | 0 | 0 | 0 | For |
| BNY Mellon | 152,329 | 0 | 0 | 0 | For |
| Dimensional | 134,251 | 0 | 0 | 0 | For |
| Invesco | 133,507 | 0 | 0 | 0 | For |
| Equitable | 120,169 | 0 | 0 | 0 | For |
| Goldman Sachs | 115,350 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 103,619 | 0 | 0 | 0 | For |
| BARON SELECT FUNDS | 100,100 | 0 | 0 | 0 | For |
Showing the 25 largest of 63 asset managers. All 63 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Prior year: 98.4% for (June 4, 2024 meeting) ▲ 0.3 pts
Description as filed by funds: To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Gary Patou
XENON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Gary Patou”): 68,936,669 for, 901,141 against, per its Form 8-K filed June 5, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The following nominees were elected as directors to serve until the 2026 annual meeting of shareholders or until their respective successors are duly elected and qualified:”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 63 asset managers below reported 25,761,595 for, 9,596 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 7,926,499 | 0 | 0 | 0 | For |
| Capital Group | 5,394,151 | 0 | 0 | 0 | For |
| Vanguard | 2,806,672 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,129,206 | 0 | 0 | 0 | For |
| JPMorgan | 765,468 | 0 | 0 | 0 | For |
| Prudential/PGIM | 686,997 | 0 | 0 | 0 | For |
| BlackRock | 661,541 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 658,823 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 499,260 | 0 | 0 | 0 | For |
| AllianceBernstein | 447,152 | 0 | 0 | 0 | For |
| Aberdeen | 437,109 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 399,759 | 0 | 0 | 0 | For |
| Loomis Sayles | 391,275 | 0 | 0 | 0 | For |
| T. Rowe Price | 317,655 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 316,679 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 277,719 | 0 | 0 | 0 | For |
| Federated Hermes | 232,500 | 0 | 0 | 0 | For |
| Putnam | 229,040 | 0 | 0 | 0 | For |
| BNY Mellon | 152,329 | 0 | 0 | 0 | For |
| Dimensional | 134,251 | 0 | 0 | 0 | For |
| Invesco | 133,507 | 0 | 0 | 0 | For |
| Equitable | 120,169 | 0 | 0 | 0 | For |
| Goldman Sachs | 115,350 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 103,619 | 0 | 0 | 0 | For |
| BARON SELECT FUNDS | 100,100 | 0 | 0 | 0 | For |
Showing the 25 largest of 63 asset managers. All 63 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Prior year: 99.9% for (June 4, 2024 meeting) ▼ 1.2 pts
Description as filed by funds: To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Gillian Cannon
XENON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Gillian Cannon”): 68,942,319 for, 895,491 against, per its Form 8-K filed June 5, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The following nominees were elected as directors to serve until the 2026 annual meeting of shareholders or until their respective successors are duly elected and qualified:”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 63 asset managers below reported 25,761,595 for, 9,596 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 7,926,499 | 0 | 0 | 0 | For |
| Capital Group | 5,394,151 | 0 | 0 | 0 | For |
| Vanguard | 2,806,672 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,129,206 | 0 | 0 | 0 | For |
| JPMorgan | 765,468 | 0 | 0 | 0 | For |
| Prudential/PGIM | 686,997 | 0 | 0 | 0 | For |
| BlackRock | 661,541 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 658,823 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 499,260 | 0 | 0 | 0 | For |
| AllianceBernstein | 447,152 | 0 | 0 | 0 | For |
| Aberdeen | 437,109 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 399,759 | 0 | 0 | 0 | For |
| Loomis Sayles | 391,275 | 0 | 0 | 0 | For |
| T. Rowe Price | 317,655 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 316,679 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 277,719 | 0 | 0 | 0 | For |
| Federated Hermes | 232,500 | 0 | 0 | 0 | For |
| Putnam | 229,040 | 0 | 0 | 0 | For |
| BNY Mellon | 152,329 | 0 | 0 | 0 | For |
| Dimensional | 134,251 | 0 | 0 | 0 | For |
| Invesco | 133,507 | 0 | 0 | 0 | For |
| Equitable | 120,169 | 0 | 0 | 0 | For |
| Goldman Sachs | 115,350 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 103,619 | 0 | 0 | 0 | For |
| BARON SELECT FUNDS | 100,100 | 0 | 0 | 0 | For |
Showing the 25 largest of 63 asset managers. All 63 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Prior year: 99.7% for (June 4, 2024 meeting) ▼ 0.8 pts
Description as filed by funds: To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Ian Mortimer
XENON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Ian Mortimer”): 69,082,169 for, 755,641 against, per its Form 8-K filed June 5, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The following nominees were elected as directors to serve until the 2026 annual meeting of shareholders or until their respective successors are duly elected and qualified:”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 63 asset managers below reported 25,761,595 for, 9,596 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 7,926,499 | 0 | 0 | 0 | For |
| Capital Group | 5,394,151 | 0 | 0 | 0 | For |
| Vanguard | 2,806,672 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,129,206 | 0 | 0 | 0 | For |
| JPMorgan | 765,468 | 0 | 0 | 0 | For |
| Prudential/PGIM | 686,997 | 0 | 0 | 0 | For |
| BlackRock | 661,541 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 658,823 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 499,260 | 0 | 0 | 0 | For |
| AllianceBernstein | 447,152 | 0 | 0 | 0 | For |
| Aberdeen | 437,109 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 399,759 | 0 | 0 | 0 | For |
| Loomis Sayles | 391,275 | 0 | 0 | 0 | For |
| T. Rowe Price | 317,655 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 316,679 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 277,719 | 0 | 0 | 0 | For |
| Federated Hermes | 232,500 | 0 | 0 | 0 | For |
| Putnam | 229,040 | 0 | 0 | 0 | For |
| BNY Mellon | 152,329 | 0 | 0 | 0 | For |
| Dimensional | 134,251 | 0 | 0 | 0 | For |
| Invesco | 133,507 | 0 | 0 | 0 | For |
| Equitable | 120,169 | 0 | 0 | 0 | For |
| Goldman Sachs | 115,350 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 103,619 | 0 | 0 | 0 | For |
| BARON SELECT FUNDS | 100,100 | 0 | 0 | 0 | For |
Showing the 25 largest of 63 asset managers. All 63 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Prior year: 100.0% for (June 4, 2024 meeting) ▼ 1.4 pts
Description as filed by funds: To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Justin Gover
XENON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Justin Gover”): 68,866,647 for, 971,163 against, per its Form 8-K filed June 5, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The following nominees were elected as directors to serve until the 2026 annual meeting of shareholders or until their respective successors are duly elected and qualified:”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 63 asset managers below reported 25,761,595 for, 9,596 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 7,926,499 | 0 | 0 | 0 | For |
| Capital Group | 5,394,151 | 0 | 0 | 0 | For |
| Vanguard | 2,806,672 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,129,206 | 0 | 0 | 0 | For |
| JPMorgan | 765,468 | 0 | 0 | 0 | For |
| Prudential/PGIM | 686,997 | 0 | 0 | 0 | For |
| BlackRock | 661,541 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 658,823 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 499,260 | 0 | 0 | 0 | For |
| AllianceBernstein | 447,152 | 0 | 0 | 0 | For |
| Aberdeen | 437,109 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 399,759 | 0 | 0 | 0 | For |
| Loomis Sayles | 391,275 | 0 | 0 | 0 | For |
| T. Rowe Price | 317,655 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 316,679 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 277,719 | 0 | 0 | 0 | For |
| Federated Hermes | 232,500 | 0 | 0 | 0 | For |
| Putnam | 229,040 | 0 | 0 | 0 | For |
| BNY Mellon | 152,329 | 0 | 0 | 0 | For |
| Dimensional | 134,251 | 0 | 0 | 0 | For |
| Invesco | 133,507 | 0 | 0 | 0 | For |
| Equitable | 120,169 | 0 | 0 | 0 | For |
| Goldman Sachs | 115,350 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 103,619 | 0 | 0 | 0 | For |
| BARON SELECT FUNDS | 100,100 | 0 | 0 | 0 | For |
Showing the 25 largest of 63 asset managers. All 63 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
92% Majority: yes · of votes cast
Prior year: 95.8% for (June 4, 2024 meeting) ▼ 4.0 pts
Description as filed by funds: To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Patrick Machado
XENON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Patrick Machado”): 64,129,706 for, 5,708,104 against, per its Form 8-K filed June 5, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The following nominees were elected as directors to serve until the 2026 annual meeting of shareholders or until their respective successors are duly elected and qualified:”
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 63 asset managers below reported 23,550,972 for, 2,220,219 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 7,926,499 | 0 | 0 | 0 | For |
| Capital Group | 5,394,151 | 0 | 0 | 0 | For |
| Vanguard | 2,806,672 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,129,206 | 0 | 0 | 0 | For |
| JPMorgan | 0 | 765,468 | 0 | 0 | Against |
| Prudential/PGIM | 686,997 | 0 | 0 | 0 | For |
| BlackRock | 661,541 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 658,823 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 499,260 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 447,152 | 0 | 0 | Against |
| Aberdeen | 437,109 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 399,759 | 0 | 0 | 0 | For |
| Loomis Sayles | 391,275 | 0 | 0 | 0 | For |
| T. Rowe Price | 317,655 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 316,679 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 277,719 | 0 | 0 | Against |
| Federated Hermes | 0 | 232,500 | 0 | 0 | Against |
| Putnam | 0 | 229,040 | 0 | 0 | Against |
| BNY Mellon | 152,329 | 0 | 0 | 0 | For |
| Dimensional | 134,251 | 0 | 0 | 0 | For |
| Invesco | 133,507 | 0 | 0 | 0 | For |
| Equitable | 19,107 | 101,062 | 0 | 0 | Mixed |
| Goldman Sachs | 115,350 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 103,619 | 0 | 0 | 0 | For |
| BARON SELECT FUNDS | 100,100 | 0 | 0 | 0 | For |
Showing the 25 largest of 63 asset managers. All 63 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Prior year: 99.7% for (June 4, 2024 meeting) ▼ 0.8 pts
Description as filed by funds: To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Steven Gannon
XENON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Steven Gannon”): 69,048,114 for, 789,696 against, per its Form 8-K filed June 5, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The following nominees were elected as directors to serve until the 2026 annual meeting of shareholders or until their respective successors are duly elected and qualified:”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 63 asset managers below reported 25,761,595 for, 9,596 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 7,926,499 | 0 | 0 | 0 | For |
| Capital Group | 5,394,151 | 0 | 0 | 0 | For |
| Vanguard | 2,806,672 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,129,206 | 0 | 0 | 0 | For |
| JPMorgan | 765,468 | 0 | 0 | 0 | For |
| Prudential/PGIM | 686,997 | 0 | 0 | 0 | For |
| BlackRock | 661,541 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 658,823 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 499,260 | 0 | 0 | 0 | For |
| AllianceBernstein | 447,152 | 0 | 0 | 0 | For |
| Aberdeen | 437,109 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 399,759 | 0 | 0 | 0 | For |
| Loomis Sayles | 391,275 | 0 | 0 | 0 | For |
| T. Rowe Price | 317,655 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 316,679 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 277,719 | 0 | 0 | 0 | For |
| Federated Hermes | 232,500 | 0 | 0 | 0 | For |
| Putnam | 229,040 | 0 | 0 | 0 | For |
| BNY Mellon | 152,329 | 0 | 0 | 0 | For |
| Dimensional | 134,251 | 0 | 0 | 0 | For |
| Invesco | 133,507 | 0 | 0 | 0 | For |
| Equitable | 120,169 | 0 | 0 | 0 | For |
| Goldman Sachs | 115,350 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 103,619 | 0 | 0 | 0 | For |
| BARON SELECT FUNDS | 100,100 | 0 | 0 | 0 | For |
Showing the 25 largest of 63 asset managers. All 63 are in the interactive database (link above).
Combines 7 wordings of this item as funds reported it.
97% Approved · of votes cast
Prior year: 97.0% for (June 4, 2024 meeting) ▼ 0.1 pts
Description as filed by funds: To approve, on an advisory basis, the compensation of the Corporation's named executive officers;
XENON PHARMACEUTICALS INC.’s own tally for this item (“2. Advisory Vote on Compensation of Named Executive Officers ("Say-on-Pay")”): 67,252,200 for, 2,125,675 against — passed, per its Form 8-K filed June 5, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The compensation of the Company's named executive officers, on an advisory basis, was approved as follows:”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 7,926,499 | 0 | 0 | 0 | For |
| Capital Group | 5,394,151 | 0 | 0 | 0 | For |
| Vanguard | 2,806,668 | 4 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,129,206 | 0 | 0 | 0 | For |
| JPMorgan | 765,468 | 0 | 0 | 0 | For |
| Prudential/PGIM | 686,997 | 0 | 0 | 0 | For |
| BlackRock | 661,541 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 658,823 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 499,260 | 0 | 0 | 0 | For |
| AllianceBernstein | 447,152 | 0 | 0 | 0 | For |
| Aberdeen | 437,109 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 399,759 | 0 | 0 | 0 | For |
| Loomis Sayles | 391,275 | 0 | 0 | 0 | For |
| T. Rowe Price | 317,655 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 316,679 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 277,719 | 0 | 0 | 0 | For |
| Federated Hermes | 232,500 | 0 | 0 | 0 | For |
| Putnam | 229,040 | 0 | 0 | 0 | For |
| BNY Mellon | 152,329 | 0 | 0 | 0 | For |
| Dimensional | 134,251 | 0 | 0 | 0 | For |
| Invesco | 0 | 133,507 | 0 | 0 | Against |
| Equitable | 120,169 | 0 | 0 | 0 | For |
| Goldman Sachs | 115,350 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 103,619 | 0 | 0 | 0 | For |
| BARON SELECT FUNDS | 100,100 | 0 | 0 | 0 | For |
Fund voting reports, all 64 managers: 25,635,410 for, 133,511 against, 9,596 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 8,479,128 | 0 | 0 | 0 | For |
| Avoro Capital Advisors LLC | 5,741,666 | 0 | 0 | 0 | For |
| Capital Group | 5,406,457 | 0 | 0 | 0 | For |
| Wellington | 3,481,536 | 0 | 0 | 0 | For |
| Janus Henderson | 3,287,150 | 4,726 | 0 | 0 | For |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 3,044,632 | 0 | 0 | 0 | For |
| BRAIDWELL LP | 2,461,141 | 0 | 0 | 0 | For |
| Commodore Capital LP | 2,375,000 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1,544,570 | 0 | 0 | 0 | For |
| Affinity Asset Advisors, LLC | 1,333,503 | 0 | 0 | 0 | For |
| JPMorgan | 1,247,590 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 1,189,903 | 0 | 0 | 0 | For |
| AllianceBernstein | 1,143,957 | 0 | 0 | 0 | For |
| Vestal Point Capital, LP | 1,125,648 | 0 | 0 | 0 | For |
| SAMLYN CAPITAL, LLC | 1,014,603 | 0 | 0 | 0 | For |
| Deep Track Capital, LP | 1,000,000 | 0 | 0 | 0 | For |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 972,855 | 3,660 | 0 | 0 | For |
| ORBIMED ADVISORS LLC | 947,877 | 0 | 0 | 0 | For |
| Rock Springs Capital Management LP | 927,950 | 0 | 0 | 0 | For |
| JENNISON ASSOCIATES LLC | 778,982 | 0 | 0 | 0 | For |
| T. Rowe Price | 773,850 | 0 | 0 | 0 | For |
| Siren, L.L.C. | 732,761 | 0 | 0 | 0 | For |
| Loomis Sayles | 615,424 | 45,437 | 0 | 0 | Mixed |
| BNP Paribas Asset Management Holding S.A. | 0 | 659,522 | 0 | 0 | Against |
| Logos Global Management LP | 650,000 | 0 | 0 | 0 | For |
Institutional-manager reports, all 165 managers: 59,019,754 for, 1,430,136 against, 447,650 abstained, 129,634 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.9% of fund votes cast · no official result
Description as filed by funds: To appoint PricewaterhouseCoopers LLP ("PwC") as the Corporation's auditor to hold office until the next annual meeting of the Corporation;
The 62 asset managers below reported 25,701,285 for, 9,596 withheld, 0 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 7,926,499 | 0 | 0 | 0 | For |
| Capital Group | 5,394,151 | 0 | 0 | 0 | For |
| Vanguard | 2,806,672 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,129,206 | 0 | 0 | 0 | For |
| JPMorgan | 765,468 | 0 | 0 | 0 | For |
| Prudential/PGIM | 686,997 | 0 | 0 | 0 | For |
| BlackRock | 661,541 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 658,823 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 499,260 | 0 | 0 | 0 | For |
| AllianceBernstein | 447,152 | 0 | 0 | 0 | For |
| Aberdeen | 437,109 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 399,759 | 0 | 0 | 0 | For |
| Loomis Sayles | 391,275 | 0 | 0 | 0 | For |
| T. Rowe Price | 317,655 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 316,679 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 277,719 | 0 | 0 | 0 | For |
| Federated Hermes | 232,500 | 0 | 0 | 0 | For |
| Putnam | 229,040 | 0 | 0 | 0 | For |
| BNY Mellon | 152,329 | 0 | 0 | 0 | For |
| Dimensional | 134,251 | 0 | 0 | 0 | For |
| Invesco | 133,507 | 0 | 0 | 0 | For |
| Equitable | 120,169 | 0 | 0 | 0 | For |
| Goldman Sachs | 115,350 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 103,619 | 0 | 0 | 0 | For |
| BARON SELECT FUNDS | 100,100 | 0 | 0 | 0 | For |
Showing the 25 largest of 62 asset managers. All 62 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Description as filed by funds: To authorize the Audit Committee of the board of directors of the Corporation to fix the remuneration to be paid to the auditors of the Corporation;
XENON PHARMACEUTICALS INC.’s own tally for this item (“4. Remuneration of Auditor”): 72,040,092 for, 24,835 against — passed, per its Form 8-K filed June 5, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The authority of the audit committee of the Board to set the remuneration of the auditor for the ensuing year was approved as follows:”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 62 asset managers below reported 25,701,285 for, 0 against, 9,596 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 7,926,499 | 0 | 0 | 0 | For |
| Capital Group | 5,394,151 | 0 | 0 | 0 | For |
| Vanguard | 2,806,672 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,129,206 | 0 | 0 | 0 | For |
| JPMorgan | 765,468 | 0 | 0 | 0 | For |
| Prudential/PGIM | 686,997 | 0 | 0 | 0 | For |
| BlackRock | 661,541 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 658,823 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 499,260 | 0 | 0 | 0 | For |
| AllianceBernstein | 447,152 | 0 | 0 | 0 | For |
| Aberdeen | 437,109 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 399,759 | 0 | 0 | 0 | For |
| Loomis Sayles | 391,275 | 0 | 0 | 0 | For |
| T. Rowe Price | 317,655 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 316,679 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 277,719 | 0 | 0 | 0 | For |
| Federated Hermes | 232,500 | 0 | 0 | 0 | For |
| Putnam | 229,040 | 0 | 0 | 0 | For |
| BNY Mellon | 152,329 | 0 | 0 | 0 | For |
| Dimensional | 134,251 | 0 | 0 | 0 | For |
| Invesco | 133,507 | 0 | 0 | 0 | For |
| Equitable | 120,169 | 0 | 0 | 0 | For |
| Goldman Sachs | 115,350 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 103,619 | 0 | 0 | 0 | For |
| BARON SELECT FUNDS | 100,100 | 0 | 0 | 0 | For |
Showing the 25 largest of 62 asset managers. All 62 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 76,586,359 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 10.35% |
| 2 | Capital Group | 7.04% |
| 3 | Vanguard | 3.66% |
| 4 | JANUS INVESTMENT FUND | 1.47% |
| 5 | JPMorgan | 1.00% |
| 6 | Prudential/PGIM | 0.90% |
| 7 | BlackRock | 0.86% |
| 8 | DRIEHAUS MUTUAL FUNDS | 0.86% |
| 9 | Bridge Builder Trust | 0.65% |
| 10 | AllianceBernstein | 0.58% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 11.07% |
| 2 | Avoro Capital Advisors LLC | 7.50% |
| 3 | Capital Group | 7.06% |
| 4 | Wellington | 4.55% |
| 5 | Janus Henderson | 4.30% |
| 6 | DRIEHAUS CAPITAL MANAGEMENT LLC | 3.98% |
| 7 | BRAIDWELL LP | 3.21% |
| 8 | Commodore Capital LP | 3.10% |
| 9 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.02% |
| 10 | Affinity Asset Advisors, LLC | 1.74% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| FMR (Fidelity) | 8,287,499 | 10.82% | Form 13F, quarter ended March 31, 2025 |
| FMR LLC | 7,851,098 | 10.25% | Proxy statement (DEF 14A), proxy filed April 24, 2025 |
| Avoro Capital Advisors LLC | 5,666,666 | 7.40% | Proxy statement (DEF 14A), proxy filed April 24, 2025 |
| Driehaus Capital Management LLC | 4,345,180 | 5.67% | Proxy statement (DEF 14A), proxy filed April 24, 2025 |
| JANUS HENDERSON GROUP PLC | 4,175,982 | 5.45% | Schedule 13G, filed May 15, 2026 |
| Entities affiliated with Wellington Management Group LLP | 4,162,654 | 5.44% | Proxy statement (DEF 14A), proxy filed April 24, 2025 |
| Wellington Management | 3,789,197 | 4.95% | Form 13F, quarter ended March 31, 2025 |
| Capital International | 3,088,730 | 4.03% | Form 13F, quarter ended March 31, 2025 |
| BlackRock | 2,036,125 | 2.66% | Form 13F, quarter ended March 31, 2025 |
| Ian Mortimer | 1,480,392 | 1.93% | Proxy statement (DEF 14A), proxy filed April 24, 2025 |
Percentages above are of 76,586,359 shares outstanding, as reported by XENON PHARMACEUTICALS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At XENON PHARMACEUTICALS INC.'s shareholder meeting held June 4, 2025, in the 2024-2025 proxy season, 210 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 2,078 separate fund positions. Their filings are grouped here into 11 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Corporation's named executive… — XENON PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 97% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: XENON PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 5, 2025.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from XENON PHARMACEUTICALS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
XENON PHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
Proxy Votes Now, “XENON PHARMACEUTICALS (XENE) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/xenon-pharmaceuticals-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.